The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1234
May 8, 2006
View Complete Issue         Table of Contents 2019 
Raloxifene (Evista) for Breast Cancer Prevention in Postmenopausal Women
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Raloxifene (Evista) for Breast Cancer Prevention in Postmenopausal Women
May 8, 2006 (Issue: 1234)
Preliminary results from a new study, unpublished but reported in a press release from the National Cancer Institute and widely disseminated in the public press, suggest that raloxifene (Evista) might be a better choice than tamoxifen (Nolvadex, and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Raloxifene (Evista) for Breast Cancer Prevention in Postmenopausal Women
Article code: 1234a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.